Digital healthcare industry is drawing
attention as non-face-to-face became a commonplace due to COVID-19 pandemic
passes through a long term. According to Global Market insights, a market research
institute, the size of the digital healthcare market is expected to grow 29.6%
annually from 106.4 billion (about 127 trillion won) in 2019, reaching $504.4
billion (about 603 trillion won) in 2025.
Especially, the main issue is the expansion of
infrastructure through blockchain technology. If block chain technology can be
used in digital healthcare industry, not only collected data can be managed
safely and transparently, but also it is possible to create a circumstance
where patients themselves can have right to control over their data.
Focusing on the core keyword ‘Immunity,’ NKCL
Bio Group is a bio incorporation that researches and develops NK cell treatment
and Immune care products that can help improve immunity. In addition to the
development and production of NK cell treatment through its own technology, it
is expanding production facility lines to enter the market of CDMO, Contract
Manufacturing Organization (CMO) and Contract Development Organization (CDO),
which is expected to grow from 13.3 billion dollars’ worth of size in 2020, and
over 13.7% grow annually.
NKCL Bio Group set automated cultivation system
where artificial intelligence (AI) applied. Specially programmed AI can find
the best cultivate environment for NK cell cultivation, so not only it replaced
existing high-quality manpower, but also achieved improved production
efficiency over 100 times and more.
GMP Automated Cultivation System operates and
enables cultivate within a closed system throughout the entire process.
Blocking any sources of contamination, the mass production of NK Cell is
possible and evaluated to maximize the price reduction by reducing labor costs
and production costs. It is expected to increase potential customers and
expanding immune cell treatment market by facilitating NK cell treatment easily
accessible. Moreover, global popularization can be achieved by exporting
automated cultivation system solutions and plants.
Because NKCL Bio Group is leading
popularization of NK cell treatment, NKCL Bio-Blockchain is getting attention
from the industry. NKCL Bio Group is constructing blockchain technology based
personal bio-data platform, NKCL Bio Blockchain. It operates and records
cultivation history, usage history and clinical results of NK Immune cell
automated cultivation on the blockchain
NKCL Bio-Blockchain is designed in a dual
structure. Customer’s bio-data are safe, manage and operate better by recorded
in private blockchain where requires separate authentication and only qualified
participants can participate and enable to access, not on the public blockchain
where anyone can access and check the details.
Medical providers, such as medical institutions
and pharmaceutical companies can contribute to medical development that
includes patients customized care, research and development through related
The issue in the medical and bio big data
industries is the connection of data standardization and data providing medical
An official from NKCL emphasizes that this is
the competitivities of NKCL platform. As an explanation, NKCL Bio-Blockchain
works for bio data that are produced in the NKCL Platform internally, it is
unnecessary to depend on medical institutions, which are comparatively
positioning in higher position, and enable to use standard data of itself.
An official from NKCL, expressing ambition,
said, “Due to COVID-19, the importance of immunity is well emphasized these
days. It is our goal to achieve competitiveness of NKCL Bio-blockchain by
expanding the non-face-to-face medical service range through enforcing data
protection and creating high added value by data collection and integration.”